Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vorice Batts

Podiatrist, Foot & Ankle Surgery Bay City, TX Doctor of Podiatric Medicine

NPI 1669849311 CMS profile 1337023

600 Hospital Cir Ste 103, Bay City, TX 77414

Open in the dashboard

General payments

$11,603

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vorice Batts of Bay City, TX is reported in the CMS Open Payments database as having received $11,603 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $491 8
2024 General $481 11
2023 General $40 1
2022 General $867 15
2021 General $1,900 26
2020 General $1,393 29
2019 General $6,431 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vorice Batts
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Vorice Batts were reported at $491. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Vorice Batts Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $6,431 $389 $118–$1,406 $163
2020 $1,393 $191 $62–$691 $114
2021 $1,900 $329 $104–$1,341 $132
2022 $867 $419 $125–$1,611 $149
2023 $40 $377 $128–$1,164 $160
2024 $481 $394 $134–$1,168 $164
2025 $491 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $7,555 81 payments
  2. Smith+Nephew, Inc. $1,589 54 payments
  3. Musculoskeletal Transplant Foundation Inc. $465 3 payments
  4. Organogenesis Inc. $439 8 payments
  5. Osiris Therapeutics Inc. $282 7 payments
  6. Bone Support Inc. $269 2 payments
  7. KCI USA, Inc $248 3 payments
  8. Treace Medical Concepts, Inc. $220 2 payments
  9. Sanara MedTech Inc. $155 1 payment
  10. Kerecis Limited $136 1 payment
  11. Other $246 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,979 169 payments
  2. Travel and Lodging $2,624 6 payments
Products named General payments · program years 2019–2025
  1. ALLOWRAP $3,137 29 payments
  2. VARIAX Trauma & Extremeties $682 4 payments
  3. HOFFMANN $678 3 payments
  4. ASNIS $651 4 payments
  5. GrafixPL $462 18 payments
  6. GRAFIX PL $454 14 payments
  7. Stravix $445 17 payments
  8. GRAFIX $419 16 payments
  9. Puraply $392 6 payments
  10. VARIAX Trauma & Extremeties $325 2 payments
  11. Other $4,667 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

149

Median for Podiatry: 160

Drug cost

$1,616

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clotrimazole Generic 100 $1,249
Doxycycline Hyclate Generic 18 $160
Mupirocin Generic 16 $112
Methylprednisolone Generic 15 $94

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$70,396

Of which drugs: $70

Medicare patients

374

Average age 75

Services billed

1,141

226 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 47%
Ischemic heart disease 36%
Chronic kidney disease 32%
Depression 21%
Atrial fibrillation 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 88 $65

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record